Recognition:
Revolutionizing Direct-to-Patient Infection Control with 235nm LED

At Surgical Site Light, we are at the forefront of a revolutionary approach to infection control with our cutting-edge 235 nm LED technology, which is applied directly to the surgical site on the patient. This innovative solution targets and eradicates drug-resistant bacteria like MRSA, a prevalent threat in surgical and chronic wound settings.

Key Insights:

• Effectiveness: Our 235nm LEDs have shown remarkable efficacy in killing MRSA, when directly applied to patients, providing a powerful alternative to traditional antibiotics.

 

• Safe Application: Research confirms that our technology is safe for human skin, minimizing DNA damage and ensuring patient safety.​

 

• Versatile Use: Ideal for surgical sites and chronic wounds, our device can be used before and during procedures to maintain a sterile environment.

​This breakthrough technology offers a promising solution to the growing challenge of antibiotic resistance, ensuring safer and more effective infection control for patients undergoing surgical procedures. 

Spectrum Medical Technologies wins the 2024 RadTech Emerging Technologies Award, presented by the International Ultraviolet Association. Founder and CEO Mark Gerber, MD, pictured.

---

Latest News:
​Using UV-C to Combat Bacteria in Surgical Settings

Surgical Site Light, the flagship medical device from Spectrum Medical Technologies, was the cover story of the 2024, Quarter 1, issue of UV Solutions. An excerpt from the article appears below. Click on the link for the full article. 

The usual disinfection treatments for chronic wound infections now are inadequate. “The problem with chronic wounds,” said Mark Gerber, founder and CEO of Spectrum Medical Technologies, “is that, in addition to the drawbacks of iodine-based solutions and chlorhexidine, a lot of patients with chronic wounds have vascular compromise.

​For these patients, antibiotics are contraindicated because antibiotics cannot get to the site of the infection in adequate concentrations due to the patients’ decreased blood flow.” Chronic wound infections can develop biofilm, a material secreted by the bacteria to protect themselves – an envelope which insulates the pathogens from topical treatments.

Chronic wound infections also are often polymicrobial – a combination of different bacterial and fungal infections – leading healthcare providers to treat the infections with a cocktail of many antibiotics to address multiple pathogens. Doing this, however, douses pathogens with ineffective as well as effective antibiotics, allowing pathogens to develop further resistance to antibiotics. Horizontal gene transfer is an issue here, too.

Click for article

---

Research Findings:
Breakthrough in Infection Control: SSL's 235nm LED Technology

At the forefront of medical innovation our team of researchers, led by Mark Gerber in partnership with Columbia University, recently tested a new prototype on MRSA cultures in vitro. Released in May 2024, the research data is promising. 

Key Findings

Highly Effective

• Surgical Site Light's LEDs have proven to kill up to 99.9% of MRSA with precise dosing.
• Specific doses needed to kill 90% and 99.9% of the bacteria were identified.

Safe for Cells

• The study looked at cell damage right after LED exposure and a week later.
  Minimal damage was observed initially and after a week, suggesting the treatment is safe for cells.

​Positive Tissue Response

• Detailed tissue analysis confirms normal and non-harmful changes in the skin post-treatment.
• No CPD induction 30 minutes after exposure.

This cutting-edge technology offers a revolutionary approach to infection control, presenting a significant market opportunity for reducing healthcare-associated infections.

Note: this research is not yet peer reviewed.
​

Click for Additional Data